Glenmark Pharmaceuticals Inc.

Glenmark Pharmaceuticals Inc. is the U.S. subsidiary of Glenmark Pharmaceuticals Ltd., a global pharmaceutical company headquartered in Mumbai, India. Founded in 1977, the parent company is publicly traded on India's National Stock Exchange and the Bombay Stock Exchange (NSE: GLENMARK). The global entity employs over 15,000 people and reported revenues of approximately $1.6 billion to $1.86 billion in recent fiscal years. The U.S. subsidiary was established in 2003, with its corporate office in Elmwood Park, New Jersey, and manufacturing and distribution facilities in North Carolina and Pennsylvania, respectively.

Glenmark operates as a research-driven, integrated pharmaceutical company with business segments in generics, specialty branded products, and over-the-counter (OTC) medications. The company focuses on developing and commercializing drugs in key therapeutic areas including dermatology, respiratory, and oncology. Its U.S. portfolio includes over 170 generic products, and the company is also working to expand its specialty branded offerings. Globally, Glenmark operates numerous manufacturing facilities and R&D centers.

As an operating company focused on generic and specialty drug manufacturing, Glenmark Pharmaceuticals Inc. is primarily a defendant in patent litigation. The provided case data shows the company in one tracked suit as a defendant, consistent with the typical patent-litigation posture of a generic pharmaceutical manufacturer, which often faces infringement suits from brand-name drug companies when seeking to market generic equivalents.

The single tracked case, Veloxis Pharmaceuticals, Inc. v. Glenmark Pharmaceuticals Inc., was filed in the U.S. District Court for the District of Delaware in 2025. This type of litigation is common in the pharmaceutical industry under the Hatch-Waxman Act, where brand-name drug manufacturers sue generic drug companies that file Abbreviated New Drug Applications (ANDAs) to market generic versions of patented drugs.